About US
Contact us
-
New hurdle for DPP-4 diabetes meds: FDA spotlights risk of 'disabling' joint painAs if last week'sJardiancenews wasn't enough to worry makers of DPP-4 diabetes drugs, theFDAhas now issued a warning that the class of meds might cause "severe and disabling" joint pain. The agency's2015/9/1
-
Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuseIt was attention-grabbing when California sued a handful of drugmakers, accusing them of lying about the safety of their high-powered painkillers and blaming them for an epidemic of prescription drug2015/8/31
-
Patient education 'useless' when it comes to Eliquis adherence: studyLONDON--Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV study of their new-age anticoagulant,Eliquis, atrial fibrillation patients posted adherence rates near 90%. And the icing2015/8/31
-
CFDA issues announcement on further standardizing naming of health foodThe revised Food Safety Law of the People's Republic of China will come into effect as of October 1, 2015. In accordance with the requirement of strict supervision to health food, China Food and Drug2015/8/28
-
The FDA has spoken on biosimilar names. But will its hybrid proposal work?After much industry lobbying and public debate, theFDAhas proposed a system for naming biosimilar drugs. It's a sort of hybrid of the generic name on one hand and the unique brand name on the other. A2015/8/28
-
On the heels of big production news, Novo Nordisk snaps up two diabetes drug developersNovo Nordisk ($NVO) has had a big week. After announcing a $2 billion manufacturing investment Wednesday--and launching a late-stage trial of its oral semaglutide drug to boot--the Danish drugmaker no2015/8/28
-
Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitorMedivation ($MDVN) made a name for itself withXtandi, the prostate cancer med that's now giving Johnson & Johnson's ($JNJ) Zytiga a run for its money. Now, it wants to challenge other drugmakers i2015/8/27
-
UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S.With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk ($NVO) will spend about $1.2 billion on its firstAPIplant in the U.S., a project that is expected to bring 7002015/8/27
-
Stock slide makes biopharma deals more enticing for Gilead (and everyone else)Analysts and investors may have been ready for Gilead Sciences ($GILD) to make an M&A move before now. But with stocks on a slide, they might be glad Gilead hasn't yet. As theWall Street Journalp2015/8/26
-
Teva bows out of voting on Mylan's proposed deal for PerrigoFriday, Mylan's ($MYL) shareholders will vote on whether the company should move ahead with its hostile bid for Perrigo ($PRGO). But Teva ($TEVA) won't be among them, despite the fact that it built up2015/8/26